Michael P DiGiovanna, MD, PhD

Associate Professor of Medicine (Medical Oncology) and of Pharmacology

Research Interests

Breast Neoplasms

Research Organizations

Cancer Center, Yale: Signal Transduction

Medical Oncology: Subset Medical Oncology Faculty

Signal Transduction

Research Summary

We study signal transduction by growth factor receptor tyrosine kinases, focusing on the EGFR/HER2/ErbB family, including the impact of signaling by these receptors on clinical outcomes and response to targeted therapies for cancer, and their potential as therapeutic targets in novel combination therapies. A major focus in our laboratory has been the interaction of HER2 signaling with estrogen receptor (ER) signaling in breast cancer, and more recently with IGF-I receptor signaling, and the effects of inhibitors of these receptors in combination targeted therapies. We have also found that in breast cancer patients, tumors harboring activated HER2 have adverse prognosis, and these tumors have co-overexpression of EGFR. We continue to study how signaling by these receptors impacts responses to different types of therapies and explore targeting these receptors in combination with other novel targeted therapeutics.

Extensive Research Description

We study signal transduction by growth factor receptor tyrosine kinases, focusing on the EGFR/HER2/ErbB family, including the impact of signaling by these receptors on clinical outcomes and response to targeted therapies for cancer, and their potential as therapeutic targets in novel combination therapies. A major focus in our laboratory has been the interaction of HER2 signaling with estrogen receptor (ER) signaling in breast cancer, and more recently with IGF-I receptor signaling, and the effects of inhibitors of these receptors in combination targeted therapies. We have also found that in breast cancer patients, tumors harboring activated HER2 have adverse prognosis, and these tumors have co-overexpression of EGFR. We continue to study how signaling by these receptors impacts responses to different types of therapies and explore targeting these receptors in combination with other novel targeted therapeutics.Therapeutic implications of interactions of IGF-I receptor with HER2 and estrogen receptor

Selected Publications

Edit this profile

Contact Info

Michael P DiGiovanna, MD, PhD
Patient Care Location
Yale Cancer CenterYale-New Haven Hospital
20 York Street, Ste NP - 1

New Haven, CT 06510
Mailing Address
PO Box 208032
300 George Street

New Haven, CT 06520-8032